Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions

January 27, 2017 updated by: Annika Hofstetter, Columbia University
There are a growing number of adolescents with chronic medical conditions in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination and annual influenza vaccination of all adolescents. Pneumococcal polysaccharide vaccination is also recommended for certain high-risk patients. Limited studies suggest that vaccination coverage of this population remains sub-optimal. Text message vaccine reminder/recall has been shown to be effective in increasing uptake of select pediatric and adolescents vaccines, but has yet to be examined among patients with chronic medical conditions who may also face unique barriers to vaccination. This intervention aims to implement and evaluate the use of text message vaccine reminders among urban low-income minority adolescents with chronic medical conditions. This investigator-initiated study is supported in part by a grant from the Pfizer Medical Education Group.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

416

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10032
        • NewYork-Presbyterian Hospital/Columbia University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Parent with

  1. adolescent aged 11-17 years;
  2. adolescent with ≥1 chronic medical condition;
  3. adolescent with clinic visit in last 12 months;
  4. cell phone number listed in hospital registration system

Exclusion Criteria:

Parent who:

  1. does not speak English or Spanish;
  2. is unwilling to receive text message vaccine reminders;
  3. anticipates moving from area in coming 12 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: educational text message reminders
receipt of education-embedded text message vaccine reminders
Other: educational text message reminders
Other Names:
  • educational text message vaccine reminders
  • education-embedded text message vaccine reminders
Active Comparator: conventional text message reminders
receipt of conventional text message vaccine reminders
Other: conventional text message reminders
Other Names:
  • conventional text message vaccine reminders

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
Time Frame: 12 weeks after intervention start
12 weeks after intervention start

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
Time Frame: 4 weeks after intervention start
4 weeks after intervention start
Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)
Time Frame: 24 weeks after intervention start
24 weeks after intervention start
Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination
Time Frame: 4 weeks after intervention start
4 weeks after intervention start
Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination
Time Frame: 12 weeks after intervention start
12 weeks after intervention start
Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination
Time Frame: 24 weeks after intervention start
24 weeks after intervention start

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Columbia University

Collaborators

Pfizer

Investigators

  • Principal Investigator: Annika M Hofstetter, MD, PhD, MPH, Columbia University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2014

Primary Completion (Actual)

June 1, 2015

Study Completion (Actual)

January 1, 2017

Study Registration Dates

First Submitted

August 15, 2014

First Submitted That Met QC Criteria

September 2, 2014

First Posted (Estimate)

September 4, 2014

Study Record Updates

Last Update Posted (Estimate)

January 30, 2017

Last Update Submitted That Met QC Criteria

January 27, 2017

Last Verified

January 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AAAM3756

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vaccination

Clinical Trials on educational text message reminders

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe